Formulary Focus: PCSK9 Drug Prices May Lead Payers To Impose Coverage Restrictions

Anticipating annual pricing of up to $10,000 per patient for PCSK9 cholesterol-lowering drugs that will be prescribed for life, payers are taking a very close look at how to limit use to the patients who most need to take the drugs in the new class instead of low-cost statins.